“From Rare to Common” strategy expanding from rare diseases into common diseases
First written in FY2023. 2 of 3 entries say "Restated". Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025RestatedAnnual report
「We will advance the “From Rare to Common” strategy of connecting research and development for intractable rare diseases with research and development for common diseases affecting larger patient populations.」
The company reiterates its strategy of expanding research and development for rare diseases into common diseases with larger patient populations. - FY2024RestatedAnnual report
「We will advance the “From Rare to Common” strategy of connecting research and development for intractable rare diseases with research and development for common diseases affecting larger patient populations.」
The company reiterates its strategy of expanding research and development from rare diseases to common diseases with larger patient populations. - FY2023First statedAnnual report
「We will advance the “From Rare to Common” strategy of connecting research and development for intractable rare diseases with research and development for common diseases affecting larger patient populations.」
The company first explicitly stated its strategy of expanding drug discovery research for rare diseases into common diseases affecting larger patient populations.